RegeneRx Biopharmaceuticals, Inc. (RGRX)
OTCQB OTCQB Primary Summary
RegeneRx Biopharmaceuticals, Inc. (RGRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RegeneRx Biopharmaceuticals, Inc. ever had a stock split?
RegeneRx Biopharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | J. J. Finkelstein CEO | OTCQB Exchange | 75886X306 CUSIP |
| US Country | 2 Employees | - Last Dividend | 18 Oct 2023 Last Split | 23 Dec 1986 IPO Date |
Overview
RegeneRx Biopharmaceuticals, Inc. is a pioneering biopharmaceutical entity centered on the advancement of Thymosin beta 4, a therapeutic peptide known for its potential in tissue and organ protection, repair, and regeneration. Originating in 1982 and originally operating under the name Alpha 1 Biomedicals, Inc., the company underwent a name change in 2000 to better reflect its core focus and direction. RegeneRx is headquartered in Rockville, Maryland, and has established strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics to bolster its development and distribution capabilities. The company dedicates its efforts towards a promising pipeline of treatments aimed at addressing a wide range of medical needs, including injuries, diseases, and conditions affecting the cardiovascular system, the central and peripheral nervous systems, and skin integrity.
Products and Services
- RGN-259
- RGN-352
- RGN-137
A groundbreaking preservative-free topical eye drop designed for the regeneration of corneal tissues that have been impaired by injuries, diseases, or other pathological conditions. RGN-259 represents a significant step forward in ophthalmic care, offering hope for patients suffering from various corneal conditions by harnessing the regenerative properties of Thymosin beta 4.
RegeneRx is taking innovative steps with RGN-352, an injectable formulation intended for the treatment of a broad spectrum of conditions, including cardiovascular diseases, central and peripheral nervous system diseases. This product leverages the systemic regenerative capabilities of Thymosin beta 4 to offer potential treatments for conditions that currently have limited therapeutic options.
A topical gel specifically formulated for the treatment of dermal wounds and the reduction of scar tissue. By applying directly to the skin, RGN-137 has the potential to accelerate the healing process of wounds and minimize the formation of scars, promoting healthier and more aesthetically pleasing skin recovery.
